Due to health issues, this site is no longer maintained and will be shut down shortly.

JT:4502 Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. It provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. The company operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. Takeda Pharmaceutical Company Limited has licensing agreements with TESARO, Inc. for the commercialization and clinical development of Niraparib, a novel poly ADP-ribose polymerase inhibitor; Denali Therapeutics for neurodegenerative disease therapeutic product candidates; and Wave Life Sciences Ltd. for central nervous system nucleic acid therapies. The company also has collaboration agreements with Rani Therapeutics LLC to conduct research on the use of the RANI PILL technology for oral delivery of Factor VIII therapy for patients with hemophilia A; Novimmune S.A. to develop and commercialize a bi-specific antibody to treat hemophilia A and hemophilia A patients with inhibitors; and AB Biosciences Inc. for a recombinant immunoglobulin product candidate and intellectual property relating to its pan receptor interacting molecule program. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.This company has ADRs that trade in the U.S. as the symbol TAK.

4,263.00 JPY
As of 03/24/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Japan
Country of incorporation:  Japan
IPO date:  01/04/1984
Stock exchange:    Tokyo Stock Exchange
Exchange country:   Japan
Market cap:   5,768,280,539,136 JPY
Current dividend yield:   4.88%
Sedol:      6870445

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy